
Oncology NEWS International
- Oncology NEWS International Vol 4 No 5
- Volume 4
- Issue 5
Companies Merge to Form NeXstar
BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to form NeXstar Pharmaceuticals, Inc. One focus of the new company will be the liposomal delivery of oligonucleotides. The company's initial product, AmBisome, is a liposomal formulation of amphotericin B, which has been approved for marketing in 16 countries for the treatment of life-threatening systemic fungal infections that fail to respond to conventional amphotericin B therapy.
BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to formNeXstar Pharmaceuticals, Inc. One focus of the new company willbe the liposomal delivery of oligonucleotides. The company's initialproduct, AmBisome, is a liposomal formulation of amphotericinB, which has been approved for marketing in 16 countries for thetreatment of life-threatening systemic fungal infections thatfail to respond to conventional amphotericin B therapy.
A phase III trial of the product in conjunction with the NationalCancer Institute has recently been announced.
Articles in this issue
almost 31 years ago
Genetic Therapy Gets NIH Patentalmost 31 years ago
Fusion Product Delivers Potent Toxin to Malignant Cellsalmost 31 years ago
Retinoic Acid May Enhance Chemo In Ovarian Ca Cellsalmost 31 years ago
Compounds Block ras Gene Function Compounds Block ras Gene Functionalmost 31 years ago
Antiangiogenesis Tested in Pediatric Tumorsalmost 31 years ago
Delivery of Effective Cyclophosphamide Metabolite Could Reduce Toxicityalmost 31 years ago
New Director Attends Office of Alternative Medicine Advisory Meetingalmost 31 years ago
Worksite Cancer Screening Boosts Employee MoraleNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































